The American Association of Clinical Endocrinology (AACE) has released its 2025 Consensus Statement and updated algorithm for the management of adults with dyslipidemia, offering concise visual guidance and tables to support clinical decision-making aimed at reducing atherosclerotic cardiovascular disease (ASCVD) and triglyceride-induced pancreatitis risk. Developed by an international multidisciplinary task force, the update builds upon the 2020 AACE algorithm and integrates current evidence and expert consensus. The 2025 algorithm outlines guiding principles for patient-centered management, comprehensive risk assessment, identification of genetic dyslipidemias, lifestyle interventions, LDL-cholesterol–lowering pharmacotherapy, approaches to statin-associated muscle symptoms, and management strategies for hypertriglyceridemia and special populations—including older adults, those receiving transgender care or HIV treatment, and pregnant or lactating individuals. Aligned with the 2025 AACE Clinical Practice Guideline for Pharmacologic Management of Dyslipidemia and consistent with other international guidance, this update emphasizes individualized therapy, ASCVD and pancreatitis risk assessment, and the integration of health equity, cost-effectiveness, and risk–benefit considerations into dyslipidemia management. Source: https://www.endocrinepractice.org/
Early-life sugar restriction during pregnancy and infancy was associated with a 34% lower risk of…
Higher levels of physical activity were associated with lower risks of all-cause dementia, Alzheimer’s disease,…
In US adults aged ≥65 years, overweight and class I–II obesity were associated with lower…
In community-dwelling older adults without prior cardiovascular disease (CVD), new or persistent heart stress (HS)—defined…
In the German multicenter study of 5,521 patients with colorectal cancer (CRC), the apparent survival…
In adults aged 75 years or older without a history of atherosclerotic cardiovascular disease (ASCVD)…
This website uses cookies.